# 2025-11796: FDA Classifies Newborn Muscular Dystrophy Screening Test as Device

2025-11796, Medical Devices; Clinical Chemistry and Clinical Toxicology Devices; Classification of the Muscular Dystrophy Newborn Screening Test, is a Federal Register rule from Health and Human Services Department, Food and Drug Administration published 2025-06-26, effective 2025-06-26; PRIA reads it as touching household money (as of 2026-11-05).

- Canonical: https://policyrisk.com/federal-register/2025-11796
- As of: 2026-11-05
- Plain-text twin of the page above; the HTML and this file carry the same facts.

## Facts
- Document number: 2025-11796
- Title: Medical Devices; Clinical Chemistry and Clinical Toxicology Devices; Classification of the Muscular Dystrophy Newborn Screening Test
- Type: Rule
- Agencies: Health and Human Services Department; Food and Drug Administration
- Citation: 90 FR 27227
- Published: 2025-06-26
- Effective: 2025-06-26
- Comments close: not stated
- Significant: no
- Touches household money: yes
- Regulation identifier numbers: none
- Last updated: 2026-11-05

## In one line

FDA Classifies Newborn Muscular Dystrophy Screening Test as Device

## Summary

The FDA is officially classifying the muscular dystrophy newborn screening test as a Class II device with special controls to ensure it’s safe and effective. This change helps babies get quicker access to this important test by easing some regulatory hurdles. The new classification is effective June 26, 2025, but has been in effect since December 12, 2019, making life easier for test makers and families alike.

## Abstract

The Food and Drug Administration (FDA, the Agency, or we) is classifying the muscular dystrophy newborn screening test into class II (special controls). The special controls that apply to the device type are identified in this order and will be part of the codified language for the muscular dystrophy newborn screening test's classification. We are taking this action because we have determined that classifying the device into class II (special controls) will provide a reasonable assurance of safety and effectiveness of the device. We believe this action will also enhance patients' access to beneficial innovative devices, in part by reducing regulatory burdens.

## Effects PRIA read

- Newborn Muscular Dystrophy Test Classified Class II: benefit, medium. The FDA classified the muscular dystrophy newborn screening test as Class II (special controls). The device is defined as an in vitro diagnostic to measure creatine kinase from dried blood spot specimens from newborns. The order is effective June 26, 2025, and the classification was applicable on D…
- Easier Pathway for Device Makers (510(k) Predicate): benefit, medium. By classifying this device into Class II via the De Novo process, the FDA allows the device to serve as a predicate so future devices of that type can be cleared through the less burdensome 510(k) process instead of De Novo or premarket approval. FDA received the De Novo request on November 4, 2019…
- Mandatory Clinical Validation Study Requirements: cost, medium. Manufacturers must perform design verification and validation that include a clinical validation study demonstrating that the analyte identifies newborns needing follow-up, shows predictive value using well-characterized specimens, uses testing by representative users, assesses sample collection ef…
- Labeling Must Show Warnings and Test Performance: benefit, low. Labeling must include warnings that results are not intended to diagnose muscular dystrophies and that results should be used with other clinical findings and confirmatory methods. Labels must provide detailed device performance information, including the false positive and false negative screen ra…

## Related documents

- [2026-20848](https://policyrisk.com/federal-register/2026-20848): Use of Salt Substitutes To Reduce the Sodium Content in Standardized Foods, 2026-10-13
- [2026-16296](https://policyrisk.com/federal-register/2026-16296): Substances Generally Recognized as Safe, 2026-08-11
- [2026-14073](https://policyrisk.com/federal-register/2026-14073): Drug Establishment Registration and Drug Listing Requirements for Establishments Engaged in Distributed Manufacturing and Certain Foreign E…, 2026-07-13
- [2026-13047](https://policyrisk.com/federal-register/2026-13047): Establishment Registration and Product Listing for Tobacco Products, 2026-06-29
- [2025-04978](https://policyrisk.com/federal-register/2025-04978): Nonprescription Drug Product With an Additional Condition for Nonprescription Use, 2025-03-25
- [2025-01840](https://policyrisk.com/federal-register/2025-01840): Nonprescription Drug Product With an Additional Condition for Nonprescription Use, 2025-01-27

## Sources
- [2025-11796 on federalregister.gov](https://www.federalregister.gov/documents/2025/06/26/2025-11796/medical-devices-clinical-chemistry-and-clinical-toxicology-devices-classification-of-the-muscular)
- [2025-11796 as published (PDF)](https://www.govinfo.gov/content/pkg/FR-2025-06-26/pdf/2025-11796.pdf)

## Related
- [Previous: 2025-11794, Medical Devices; Immunology and Microbiology Devices; Classification of the Her…](https://policyrisk.com/federal-register/2025-11794)
- [Next: 2025-11802, Special Local Regulation; Marine Events; Annual Bayview Mackinac Race, Lake Hur…](https://policyrisk.com/federal-register/2025-11802)
- [All Federal Register documents](https://policyrisk.com/federal-register)

Source: PRIA, https://policyrisk.com/federal-register/2025-11796 (as of 2026-11-05).
